一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Infectious disorders drug targets >>article

Infectious disorders drug targets

Download PDF

Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment?

Published:1 January 2020 DOI: 10.2174/1871526518666180816101124 PMID: 30113002
Deepti Chopra, Bharti Bhandari

Abstract

Chronic hepatitis C remains a major public health concern with a prevalence of more than 1% worldwide. Of late, with the discovery of newer drugs, chronic HCV treatment has touched new dimensions. The treatment has progressed from Interferons to Pegylated interferon (Peg IFN) based therapy, with or without ribavirin to treatment with orally active Direct Acting Antivirals (DAA) with Peg IFN and ribavirin and eventually to various combinations of DAA, without IFN. Introduction of newer DAAs has transfigured the treatment of chronic HCV. Chronic HCV patients with advanced liver disease, psychiatric condition, anemia or autoimmune diseases, not eligible for Peg IFN based therapy have a ray of hope now. Amongst all DAAs, nucleoside inhibitors have been the most promising agent. Thus the present review focuses on Sofosbuvir, one of the most effective nucleoside inhibitors; in terms of potency, resistance profile, activity against all genotypes of HCV and adverse effects. FDA approved Sofobuvir for clinical use in 2013. Chemically, it is 2'-deoxy-2'-α-fluoro-β-Cmethyluridine- 5'-triphosphate; a phosphoramidate prodrug that is activated by enzyme present in human liver. It is a highly potent inhibitor of HCV NS5B polymerase. Efficacy of the Sofosbuvir has been established in various phase 2 and phase 3 clinical trials like PROTON, ELECTRON, FUSION, POSITRON etc. Sofosbuvir has a good safety profile with few mild to moderate adverse effects. Evidence reveals that sofosbuvir has substantial impact on the treatment of HCV.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Sofosbuvir 1190307-88-0 C22H29FN3O9P 615 suppliers $16.00-$3990.00
2'-O-Methyl-5-methyluridine 5'-triphosphate triethylammonium salt 444789-41-7 C11H19N2O15P3 8 suppliers Inquiry

Similar articles

IF:4.6

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.

Clinical Pharmacokinetics Brian J Kirby, William T Symonds,etc Published: 1 July 2015
IF:1.3

Lamivudine treatment for acute severe hepatitis B: report of a case and review of the literature.

Acta gastro-enterologica Belgica A Roussos, S Koilakou,etc Published: 1 January 2008
IF:0

C-Arylglucoside synthesis: triisopropylsilane as a selective reagent for the reduction of an anomeric C-phenyl ketal

Tetrahedron, asymmetry B. Ellsworth,?A. Doyle,etc Published: 17 October 2003
抚顺县| 武宁县| 略阳县| 普洱| 平安县| 林甸县| 酒泉市| 东乡| 临清市| 巴楚县| 西安市| 汤阴县| 同心县| 新闻| 重庆市| 梨树县| 恩施市| 中方县| 河源市| 夏邑县| 涟水县| 凤城市| 青海省| 乐业县| 湖北省| 介休市| SHOW| 河北省| 体育| 晴隆县| 郓城县| 唐海县| 长泰县| 论坛| 革吉县| 太仓市| 景谷| 寿宁县| 剑阁县| 涞源县| 兴安盟|